FDA likely to OK Sage's postpartum depression drug

The first-ever drug to treat postpartum depression, developed by Cambridge-based Sage Therapeutics Inc., appears set for likely approval by the FDA after favorable votes on three key questions by members of an advisory committee Friday. The 18 members of the FDA's Psychopharmacologic Drugs Advisory Committee voted unanimously to say the trial data on the drug by Sage (Nasdaq: SAGE), which would be sold as Zulresso, provided "substantial evidence ... to support a claim of effectiveness... for the…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news